Difference between revisions of "Part:BBa K4361314"
Line 27: | Line 27: | ||
<html> | <html> | ||
<h3>Usage and Biology</h3> | <h3>Usage and Biology</h3> | ||
− | The set of BlcR mutants (</html>[[Part:BBa_K4361300]] through [[Part:BBa_K4361319]]<html>) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (<b>Figure 1.</b>) to determine whether or not the protein was produced. For this mutant (<u>lane 15</u>), a band | + | The set of BlcR mutants (</html>[[Part:BBa_K4361300]] through [[Part:BBa_K4361319]]<html>) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (<b>Figure 1.</b>) to determine whether or not the protein was produced. For this mutant (<u>lane 15</u>), a protein band corresponding to the BlcR monomer is visible. Concluding that the production in an E. coli cell-free system was successful for this mutant. |
− | + | ||
<figure> | <figure> | ||
<a href="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-15.png"><img src="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-15.png" style="width:600px;margin-left:125px"></a> | <a href="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-15.png"><img src="https://static.igem.wiki/teams/4361/wiki/results/figure-7-pure/figure-7-pure-15.png" style="width:600px;margin-left:125px"></a> | ||
− | <figcaption> <b>Figure 1.</b> SDS PAGE | + | <figcaption> <b>Figure 1.</b> SDS PAGE showing the translation products of 20 different plasmids coding for BlcR mutants. PURE reaction solution was supplemented with GreenLys and the synthesized proteins were imaged with Typhoon using a 488-nm laser. C: negative control with no plasmid. WT: positive control with expressed wildtype BlcR. 15: A67V mutant.</figcaption> |
</figure> | </figure> | ||
Latest revision as of 15:57, 12 October 2022
BlcR A67V
A mutant of the BlcR protein, created through site-directed mutagenesis with primers R3 (Part:BBa_K4361218) and F3.5 A67V (Part:BBa_K4361223). For this mutant, the alanine in position 67 has been changed to valine by mutating the GCG codon to GTG.
This mutant also contains the following nucleotide mutations outside of the targeted site:
- G 482 > T, resulting in substitution G161V
- G 670 > T, resulting in substitution A224S
- G 677 > T and T 678 > G, resulting in substitution R226L
- G 716 > C, resulting in substitution S239T
- G 765 > A, silent mutation
- G 787 > C, resulting in substitution A263P
Sequencing data only contained this part's sequence up until and including nucleotide 791. All nucleotides after are presumed to be identical to those found in the original codon optimized BlcR, Part:BBa_K4361100.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 694
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 78
- 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 589
Usage and Biology
The set of BlcR mutants (Part:BBa_K4361300 through Part:BBa_K4361319) were expressed in a PURE system in the presence of GreenLys (fluorescent Cy2-labeled lysine). Samples were then run on an SDS PAGE gel (Figure 1.) to determine whether or not the protein was produced. For this mutant (lane 15), a protein band corresponding to the BlcR monomer is visible. Concluding that the production in an E. coli cell-free system was successful for this mutant.